Podcasts about Hologic

In the latest episode of the SALT Shaker Podcast, Eversheds Sutherland Counsel Jeremy Gove and Chelsea Marmor explore a new, concise podcast format that provides updates on recent noteworthy cases. Jeremy and Chelsea examine a New Hampshire court's decision in Hologic, Inc. v. Stepp, covering the facts, the court's holding, the analysis, and the case's practical implications. They wrap up the episode with a new segment, asking “either/or” – do you prefer the vernal equinox or autumn equinox? You can read our summary of Hologic, Inc. v. Stepp here. For questions or comments, email SALTonline@eversheds-sutherland.com. Subscribe to receive regular updates hosted on the SALT Shaker blog.

LIVE from Transform 2025 in Las Vegas! Amira Barger is an award-winning Executive Vice President of Communications and Head of DEI Advisory at Edelman, providing senior reputation management and polycultural counsel to clients across the globe. Recently named Woman of the Year by Women Health Care Executives, Top 100 Executives by Involve People, Top CMOs of 2024 by the CMO Alliance, Top 50 Global DEI Professionals by OnConferences, Top 100 People Leaders by Mogul, Fearlessly Authentic Leader by Leaderology, and 30 under 40 in Healthcare Innovation by Business Insider – Amira is a scholar, practitioner and thought leader who brings more than 20 years of experience in strategic communications that reach stakeholders, mobilize the community and inspire action. Amira has global experience in pharma/healthcare communications, corporate branding, web and social media, M&A experience, media relations, team management, sustainability/social impact, reputation management, and DEI. Throughout her career, Amira has utilized these competency areas for clients such as: CVS Health, Eli Lilly, Walgreens, Hologic, Genentech, Pfizer, GSK/Haleon, BMS, Zoetis, Alkermes, Regeneron, Amgen, Medtronic, Children's Miracle Network, Kaiser Permanente, First 5 Los Angeles, Covered California, Centers for Disease Control and Prevention, FEMA, and California Community Colleges. Adam and Amira discuss: - How does “niceness” in workplace culture hold back real DEI progress, and what should leaders do instead? - Challenging Workplace Norms to Advance DEI and Justice - Empowering Women in Leadership - Valuing the Whole Human - "How can leaders move beyond surface-level well-being initiatives to truly create workplaces that honor employees as whole humans, not just workers? Connect with Amira: https://www.linkedin.com/in/amirabarger/ Live from Transform 2025, we're bringing you an exclusive podcast series packed with insights from some of the brightest minds in hiring, talent strategy, and workforce transformation! In this series, we've got incredible guests from Okta, Tubi, Edelman, Greenhouse, Findem, and more, sharing how top organizations are rethinking hiring, culture, and talent acquisition in today's fast-changing world. Greenhouse combines a structured, data-driven hiring approach with AI-embedded workflows that empower recruiters to focus on strategic, high-impact work. From sourcing top talent to personalizing the candidate experience, Greenhouse streamlines and optimizes the entire hiring process. This ensures that every hire is the right hire—eliminating bias, creating fairness, and helping teams make smarter, faster decisions. Over 7,500 companies, including HubSpot, Duolingo, and J.D. Power, trust Greenhouse to build better teams and turn talent into a strategic advantage. Want to learn how today's top companies are winning the talent game? Tune in now and visit Greenhouse.com to transform the way you hire. Thanks for listening. Please follow us on Instagram @NHPTalent and X @AdamJPosner. Visit www.thePOZcast.com for all episodes

Welcome to the Health Marketing Collective, where strong leadership meets marketing excellence. Today, in today's episode, Julia Steele Rodriguez joins us to discuss the critical role of Key Opinion Leaders (KOLs) in healthcare marketing. Julia, who led key teams in the breast and skeletal health division at Hologic, shares her vast experience in building and nurturing KOL programs across various med device companies. Throughout the episode, host Sara Payne and Julia discuss the intricacies of engaging KOLs effectively to enhance brand trust, communicate complex information, and foster both clinician and patient education. Together, they explore how to define what a KOL means within an organization, strategies for identifying and selecting the right KOLs, and the dynamics that make for a successful, long-term KOL partnership. Thank you for being part of the Health Marketing Collective, where strong leadership meets marketing excellence. The future of healthcare depends on it. Key Takeaways: Defining KOLs: Julia emphasizes the necessity of having a clear, shared definition of a KOL within an organization. Aligning on this definition ensures that everyone understands that KOLs are influential figures who can impact healthcare professionals and patients beyond their own organization. Identifying the Right KOLs: Strategies include researching publications, conferences, and professional societies to find those who are influential in their field. Julia stresses the importance of considering both objective data and subjective elements like personality and organizational fit. Fostering Long-Term Relationships: For KOL partnerships to be successful, they must be mutually beneficial. This involves understanding the KOLs' interests and ensuring they find value in the partnership, be it career development or influencing market innovations. Challenges in KOL Programs: Successful KOL partnerships require seamless internal processes, such as contracting and communication, as well as clear expectation setting and regular updates to maintain engagement and trust. Impact of KOLs on Marketing Strategy: Effective KOL partnerships can significantly influence healthcare marketing strategies, as evidenced by Hologic's success in advancing three-dimensional mammography as the standard of care. KOLs can powerfully advocate for policies, enhancing both market presence and healthcare access. This insightful conversation with Julia offers valuable perspectives on integrating KOLs into healthcare marketing efforts, underscoring their role in advancing organizational objectives and healthcare outcomes. [embed]https://youtu.be/oaAmR-Mk3zE[/embed]

Women's health remains a critical issue globally, with alarming disparities in access and outcomes. A new survey from Hologic and Gallup reveals that while nearly 90% of women recognize the importance of health screenings, less than half undergo them consistently due to barriers like cost, time, and anxiety. The stakes are particularly high in underserved communities, where delayed diagnoses can lead to advanced cases of conditions like cervical and breast cancer.What can be done to ensure equitable access to healthcare for all women, especially in marginalized and rural areas? Can artificial intelligence revolutionize screening and diagnostics to save lives?On I Don't Care, host Dr Kevin Stevenson has a chat with Mia Keeys, Director of Global Health and Innovation at Hologic. Together, they delve into the intersection of equity, technology, and advocacy in women's health.Key Takeaways:Barriers to Women's Health Access: Structural challenges like transportation, affordability, and cultural trust hinder consistent screenings, despite widespread recognition of their importance.AI's Role in Healthcare: AI technologies, such as Hologic's digital cytology for cervical health, enhance efficiency in diagnostics and provider workflows, addressing burnout and improving care.Advocacy for Policy Change: Maintaining healthcare access through programs like the Affordable Care Act and expanding support for underserved areas are pivotal in improving outcomes.Dr. Mia Keeys is a global health expert and director at Hologic, focusing on women's health innovation and equity. A former chief of staff for Congresswoman Robin Kelly, she has spearheaded health equity initiatives in Congress, at the American Medical Association, and abroad. Her academic pursuits include health policy and artificial intelligence, with field experience in countries like Indonesia and South Africa.

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) CEO Doug Ward takes Proactive's Stephen Gunnion through the company's achievements in 2024 and plans for the year ahead. Ward highlighted several key milestones, including the signing of a strategic partnership with Hologic and progress with its flagship products, ViraDx and FebriDx. He emphasised that FebriDx is transforming treatment by differentiating between bacterial and viral infections, helping to combat antibiotic resistance. Ward also discussed Lumos's collaboration with the Biomedical Advanced Research and Development Authority (BARDA), which funded a clinical trial to expand FebriDx's accessibility. He noted, “This is a huge win for Lumos, enabling us to go from 18,000 locations to 220,000 locations in the US with CLIA waivers.” Furthermore, the company successfully secured A$10.00 million in funding, attracting key investors like Tenmile and Ryder Capital. Ward expressed optimism for 2025, focusing on revenue growth, the BARDA-funded trial, and enhancing their partnerships. Visit Proactive's YouTube channel for more insightful interviews. Don't forget to like, subscribe, and enable notifications for future updates! #LumosDiagnostics #FebriDx #DiagnosticInnovation #AntibioticStewardship #HealthcareSolutions #HologicPartnership #BARDA #PointOfCareTesting #MedicalDevices InvestmentNews #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Michael Quick is a cytologost currently serving as the VP of R&D and Innovation for Cytology and Oncology at Hologic and the 2024 DPA President. Mike shares his background as a cytologist and how it led to a career focused on innovation in the digital pathology industry. Hologic has grown into the digital pathology and laboratory industry, and we discuss motivations for expansion of a large company into new areas of medicine. Finally, we feature an interview from Pathology Visions 2024 where Mike reflects on the conference and accomplishments as DPA President.A forum to engage with the hosts and other listeners has been launched on the DPA website www.digitalpathologyassociation.org. DPA members may login to the DPA Collaborate hub (under the Resources tab) and join the Beyond The Scope community. All listeners are encouraged to use this forum to suggest future topics and guests, submit questions and corrections, and provide general feedback.

Approximately 50,000 East and Gulf Coast port workers began a strike last night. Investor and Boston Celtics owner Glenn Hutchins discusses his perspective on the strength of the economy and the possibility of a soft landing for the Fed. Next, Steve MacMillan, CEO of diagnostic maker Hologic, talks about breast cancer awareness and how his company is using AI to help detect cancer. Plus, the death toll from Hurricane Helene has reached 130 people and legendary baseball player Pete Rose has died at age 83. Glenn Hutchins - 12:18Steve Macmillan - 27:19 In this episode:Becky Quick, @BeckyQuickJoe Kernen, @JoeSquawkAndrew Ross Sorkin, @andrewrsorkinZach Vallese, @zachvallese

The thought of your teen making a life-altering mistake because of alcohol is terrifying. We know that underage drinking can lead to devastating consequences, from impaired driving accidents to the dangerous combination of alcohol with other drugs. But here's the thing—these tragedies are entirely preventable. To help us navigate this tough topic, I'm joined by Stacey D. Stewart, CEO of Mothers Against Drunk Driving (MADD). Stacey is going to share how we, as parents, can address this fear, take action, and keep our teens safe from the dangers of drinking.   Key Takeaways ➡️ Underage drinking and impaired driving are still major issues with devastating consequences. ➡️ Parents play a crucial role in preventing underage drinking and impaired driving by having open and ongoing conversations with their children. ➡️ Providing information and resources to children helps them make informed decisions and understand the dangers of alcohol and substance use. ➡️ Parents should model responsible behavior and seek help if their child is struggling with substance use. Meet Today's Guest: Stacey D. Stewart Stacey D. Stewart is the CEO of Mothers Against Drunk Driving (MADD).  For more than 25 years, Stacey has served in purpose-driven roles including President and CEO of the Fannie Mae Foundation, U.S. President and Executive Vice President for Community Impact Leadership and Learning at United Way Worldwide (UWW), and most recently the President and CEO of March of Dimes. Stewart is a graduate of the Ross School of Business at the University of Michigan where she earned an MBA in Finance and a Bachelor of Arts degree in Economics from Georgetown University and holds numerous honorary degrees. She has been a director on more than 40 non-profit boards, nationally, and in the Washington, D.C. Metropolitan Area.  Stewart also serves on the boards of Hologic, Inc., a medical technology company focused on women's health and PennyMac Mortgage Investment Trust, a residential real estate investment trust.  Stacey is a mother to two college-age daughters and resides in Bethesda, MD with her husband. Connect with Stacey Website | Instagram | Facebook | LinkedIn | X | YouTube | TikTok   Meet Your Host: Dr. Cam Cameron (Dr. Cam) Caswell, a.k.a. "The Teen Translator," gets it! As an Adolescent Psychologist & parent of a teen, she knows the struggles of navigating those tough years firsthand. As a private practitioner, TEDx speaker, podcast host, and author, she offers hope and practical strategies to help parents unlock their teen's confidence & resilience, build deeper, stronger connections with them, and foster a positive home environment. Listen to her podcast, "Parenting Teens with Dr. Cam," and follow her in Instagram @drcamcaswell for actionable advice. Connect with Dr. Cam Website | Instagram | TikTok | YouTube   Resources Mentioned in This Episode FREE QUIZ: Are You on the RIGHT Track With Your Teen? MADD's digital Power of Parents handbook Thanks so much for listening to our podcast! If you enjoyed this episode and think that others would appreciate the guidance and encouragement, please take a quick moment to rate and review. Reviews from my listeners are extremely valuable and greatly appreciated. Review on iTunes. Subscribe to the Podcast If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on iTunes, YouTube, Spotify. You can also subscribe from the podcast app on your mobile device.   ABOUT THE SHOW: The 'Parenting Teens with Dr. Cam' Podcast: Your Guide to Navigating Adolescence Without the Drama. Hosted by Cameron (Dr. Cam) Caswell, an adolescent psychologist specializing in empowering parents and nurturing teen development. In each episode, she partners with a guest expert to deliver invaluable insights and practical advice for building a closer relationship with your teen & finding joy amidst the challenges Whether you're an experienced parent looking to enhance your teenager's mental well-being and strengthen your connection, or a newcomer to the world of adolescence, this podcast is a must-listen.    #ParentingTeens  #Podcast #teenagers #parentingpodcast #TeenMentalHealth #MentalHealthAwareness #drcamcaswell #theteentranslator #TeenSafety #UnderageDrinkingPrevention #MADD #TalkAboutAlcohol #ParentingSupport

Lumos Diagnostics Ltd (ASX:LDX, OTC:LDXHF) chief technology officer Sacha Dopheide joins Proactive's Tylah Tully to discuss an extended agreement with Burnet Diagnostics Initiative (BDI) to further develop and manufacture a liver function test based on Alanine Transaminase (ALT) levels. The BDI agreement includes the production of ALT lateral flow tests, customised Lumos readers and a mobile application for use in an upcoming US clinical trial. The partnership, which began with a feasibility project in July 2023, aims to address critical clinical needs through rapid point-of-care testing. The new phase of the collaboration is set to begin in August 2024 and will focus on the production of a point-of-care ALT testing system, specifically designed to monitor liver function in high-risk patients. The ALT test is expected to provide rapid results, enabling quicker detection of acute liver toxicity, potentially caused by drug reactions. Lumos will offer development, regulatory and manufacturing services over the next 9-12 months, with projected revenues between US$700,000 and US$1 million. If successful, Lumos may continue to support BDI in further development stages, including additional trials and regulatory submissions. The partnership underlines Lumos' commitment to advancing point-of-care diagnostics and improving patient outcomes. Partnerships and agreements form a large part of the company's revenue stream helping it leverage its other client offerings. #Proactiveinvestors #LumosDiagnostics #ASX #HealthcareInnovation, #FDAApproval, #PointOfCare, #MedicalDiagnostics, #WomensHealth, #Hologic, #FebriDx, #ViraDx, #FluSeason, #GlobalHealthcare, #MedicalDevices, #HealthcareSolutions, #RevenueGrowth, #StrategicPartnerships, #Diagnostics, #Biotech, #HealthcareTechnology, #FinancialResults, #MedTech #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Leslie Picker and Brian Sullivan tackle today's biggest Money Movers from the floor of the New York Stock Exchange. 

In this episode, Dr. Amy Brenner, a seasoned surgeon specializing in women's health treatments, sits down with Denise Lyon, an expert on the innovative Acessa procedure for fibroids. Together, they delve into the complexities of fibroids, discussing their impact on women's lives, symptoms, and treatment options. Key Talking Points: Understanding Fibroids: Denise Lyon explains that fibroids are benign tumors of the uterus, influenced primarily by estrogen. They can grow in different locations—inside the uterine cavity (submucosal), within the uterine wall (intramural), or outside the uterus (subserosal)—each location impacting symptoms differently. Prevalence and Impact: Up to 77% of women may develop fibroids, often leading to heavy bleeding (menorrhagia), pressure symptoms, pain, and other discomforts affecting daily life. Treatment Options: Dr. Amy Brenner outlines a range of treatments from conservative approaches to more invasive procedures like hysterectomy. They discuss the benefits of Acessa, a minimally invasive laparoscopic procedure designed to shrink fibroids without the need for major surgery. Acessa Procedure Explained: Densie and Dr. Brenner detail the Acessa procedure, highlighting its use of ultrasound to target and destroy fibroid tissue with minimal disruption. They compare it favorably to other treatments in terms of recovery time, pain management, and efficacy. Patient Considerations: The conversation covers why Acessa might be chosen over other methods, especially for patients with bulk symptoms or specific fibroid characteristics. Success and Recovery: They share data on Acessa's success rates, reduction in bleeding, and patient satisfaction, emphasizing its long-term benefits and quicker recovery compared to traditional surgeries. Patient Experience: Dr. Amy Brenner discusses what patients can expect post-procedure, including pain management, recovery timeline, and when they can anticipate relief from symptoms. Join Dr. Amy Brenner and Denise Lyon as they unpack the complexities of fibroids and explore how the Acessa procedure is reshaping treatment options for women seeking relief from this common condition. Learn about the Acessa Procedure in Cincinnati like and subscribe!  Instagram- https://www.instagram.com/amybrennermd/ Facebook- https://www.facebook.com/DoctorAmyBrenner YouTube- https://www.youtube.com/c/AmyBrennerMD Special Guest - Denise Lyon Denise Lyon is a market development specialist with Hologic, Inc., an innovative medical technology company dedicated to enhancing women's health and wellbeing. With a biology degree from Capital University and a surgical technology degree from Cincinnati State, Denise brings nearly nine years of experience at Hologic, having served in roles ranging from surgical medical science liaison to her current position. Before joining Hologic, Denise gained extensive experience as a surgical technologist at Good Samaritan Hospital. Her career is driven by a profound passion for women's health, advocating for increased education, innovation, and investment in the field.

In this episode of DeviceTalks AI, we explore the advancements in AI-driven technologies in women's health and cancer diagnostics. In our keynote interview, we speak with Michael Quick, Vice President of R&D and Innovation in Cytology & Oncology at Hologic. Quick shares his journey from a pre-med student to a leader in cytology innovation. He discusses the development and impact of Hologic's Genius Digital Diagnostic Systems, the first FDA-approved digital cytology system, which leverages AI to enhance cervical cancer screening accuracy and efficiency. Michael emphasizes Hologic's dedication to women's health and the critical role of AI in addressing the shortage of skilled cytologists, ensuring faster and more accurate diagnostics for patients worldwide. He also touches on the challenges and opportunities faced during the FDA approval process and the importance of early and collaborative engagement with regulatory bodies. We also hear from Dr. Wael Yared, Chief Technology Officer at Tecan, who highlights Tecan's contributions to cancer research and diagnostics. Dr. Yared elaborates on the company's innovations in liquid biopsy and solid tissue biopsy workflows, which leverage AI to streamline processes and reduce errors. He emphasizes the significance of partnerships in driving medical advancements and the role of AI in personalized medicine and multiomic capabilities. This conversation comes to you courtesy of our episode sponsor, Tecan Group Ltd. To learn more about Tecan visit, https://partnering.tecan.com/ Please subscribe to DeviceTalks AI on all major podcast channels and subscribe to DeviceTalks on YouTube to ensure you never miss an episode. Thank you for listening to DeviceTalks AI!

It's Episode 101 and the highlight is Tracy an Elisabeth's interview with Tracy Minutolo—Head of Operational Excellence at the technology health company Hologic. We'll find out how Tracey morphed from a microbiologist into a Lean Six Sigma Black Belt. For Hot Apps, we'll give you our take on a serious rival for ChatGPT—or a perfect companion for Google—or both. And then we'll dig into a question that came up recently about our negativity bias—is it a force for good or evil? In the meantime, fill that mug and get comfy! 0:00 - Intro 1:37 - What's on the menu? 2:23 - Hot Apps Perplexity 9:42 - Q&A Negative bias - a force for Good? 16:00 -Featured Guest Tracey Minutolo 38:48 - Upcoming Events Webinar: Good Data, Poor Data: Elevating Your Data Quality "5S Baby" Spoof Lean Rap Video Reveal Party Resources: Multiple-award-winning book, "Picture Yourself A Leader" Lean Parody Video, "Baby Got Tools!"  Thanks for Listening! Listen to more podcasts at JITCafe.com. Link to the video version of this podcast: https://youtu.be/vIUn3Sa2qTo Find us on: Apple Podcasts Podbean Spotify RSS Feed: https://feed.podbean.com/JITCafe/feed.xml 

Part 3 of 3. My guest for this week's episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics. Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.

In this episode of Medsider Radio, we had an engaging conversation with Marissa Fayer, CEO of DeepLook Medical. This startup is developing AI-powered diagnostic tools that help radiologists detect cancerous lesions in dense tissue.   Marissa has over two decades of experience as a medtech executive, entrepreneur, investor, and philanthropist, spanning companies like Hologic and Olympus. She's the founder of HERhealthEQ, a non-profit focused on advancing global women's health, and an entrepreneur-in-residence at Graybella Capital and Goddess Gaia Ventures. She's a TEDx Speaker, a UCSC Miller Center Social Entrepreneur Fellow, and winner of the 2022 First in FemTech award. In this interview, Marissa talks about the basics of product development, how to build iteratively, tips on identifying ideal regulatory pathways, and how she picks her advisors and board members.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Marissa Fayer.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerReshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerReshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerReshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerReshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerReshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerReshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Welcome everyone to the weekly San Diego Tech News by Neal Bloom and Fred Grier from Fresh Brewed Tech. I'm Neal Bloom from Fresh Brewed Tech, the Tacos and Tech Podcast, and Interlock Capital. I'm Fred Grier, journalist and author of The Business of San Diego substack. I wrote about the tech industry for the San Diego Business Journal for two years. I covered the ins-and-outs of the startup world for much of that time, breaking news on IPOs, fundraising rounds, and M&A. Before we dive in, we wanted to ask our listeners and SD Tech fans to help us grow the show, leave a review and share with one other person who should be more plugged in with the SD Tech Scene. Thank you for the support and for helping us build the San Diego Startup community. 2/13/2024 News More multi-billion $ biotech exits Inhibrx - $2.2B Axonics in OC - $3.7B Talked Ambrx for $2B already Tyra & many other post-IPO raises   $200M for Tyra Biosciences $150M for Kura Oncology   Eggscape Entertainment - $4.25M seed Trust & Will recent raise Touchdown Ventures, Erie Ventures, Comcasts' LIFT Labs Aptera - $33m in crowdfunding   New fund alert! TL Fund by Connect - $15m, all proceeds go back into the fund   Super Bowl ads In the past - Clickup, Hologic, Cue Cue Health - layoff 30% of workforce   Events - For full list - check The Social Coyote North County meetup debrief SD VC 2024 Outlook - Feb 13 AgX Hackathon March 7-9

Carl Quintanilla and Sara Eisen tackle today's biggest Money Movers from the floor of the New York Stock Exchange. 

The Hologic Global Women's Health Index is one of the most comprehensive initiatives measuring the state of health for 97% of the world's women and girls. Though the pandemic may be over, the Index reveals that women's health is no better now than it was at the height of it -- and in some cases, women's health is now worse. Laura Gillespie, vice president for Women's Health Initiatives at Hologic, joins the podcast to discuss women's testing for deadly diseases, their emotional health and their experiences across the world. “The Index findings make it exceedingly clear that it's time for world leaders to take a bolder stand for women and girls,” Gillespie says. “Women are the backbone of families, the backbone of communities and economies -- and investing in women's health benefits all of us.”

Schätzungen zufolge leiden bis zu einem Viertel aller Frauen unter einer starken, mitunter langanhaltenden Menstruationsblutung, einer Menorrhagie [1]. Die Patientinnen sind im Alltag häufig stark eingeschränkt. Über aktuelle Therapiemöglichkeiten für die Patientinnen berichtet unser Experte Prof. Dr. Becker.

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, September 22, 2023. Check out the show notes for links to the stories we discuss today at MassDevice.com/podcast. There are more funding raises in the news this week. The first one is from MedTrace, which raised $19 million for its PET-boosting technology. Fast Five hosts Sean Whooley and Danielle Kirsh go over what the funding will go toward and the technology they're developing. ProSomnus is raising $10 million for its CPAP alternative. Find out what the technology is and how optimistic executives are about the future of the technology. Whooley details a regulatory nod for Quantum Surgical's surgical robot in China. Hear about what the robot does, what kind of treatment it offers and what executives think about the regulatory nod. Medtronic Diabetes is having a good year – its Simplera CGM in InPen just won CE mark approval. Whooley and Kirsh discuss what technology and when Medtronic expects to launch the CGM. Hologic and Bayer have announced a partnership to improve mammography imaging. The Fast Five hosts go over the goal of the partnership and how the company plans to meet that goal.

Today on the podcast I am syncing up with WTA President, Micky Lawler.  As head of the Women's Tennis Association, the organization founded by Billie Jean King in 1973, Micky oversees the organization representing more than 1,600 athletes across 85 countries and hosting more than 50 annual events and four Grand Slams. It is the 50th Anniversary of the WTA and US Open this year and syncing up with Micky is an amazing way to get the ball rolling when it comes to the world of Tennis.  She is a true thought leader and game changer!  Micky was recently honored by Forbes on the 50 over 50 list as her work has been truly instrumental in the world of women's tennis and the WTA. She is responsible for expanding the WTA Tour in China and Asia more broadly. This expansion has included forging broadcast deals, setting record prize money and creating new tennis events for women in the sport. During our conversation, we talk about where her career in Tennis began and how she has played an integral role in the growth of Women's Tennis and the WTA over the years. We do a deep dive into the WTA partnerships and the role they play in expanding the sport and empowering athletes for success with tools for training, recovery, mental health, business and finance education  including most recent sponsorships with Hologic and Morgan Stanley as well as other partners SAP, Whoop, Modern Health.   I get behind the scenes intel on the ideation and production of Break Point, the amazing Tennis Docuseries on Netflix and how it came to fruition.  And of course, I get the scoop on the exercise and wellness fueling Micky for success as a busy executve, always on the move! About the WTA: Founded by Billie Jean King in 1973 on the principle of equal opportunity, the WTA is the global leader in women's professional sports. The WTA is one of the world's most recognizable and high-profile sports organizations, consisting of more than 1650 players representing approximately 85 nations, all competing to earn WTA rankings points and prestigious tournament titles. The WTA Tour comprises of over 50 events and four Grand Slams, spanning six continents and nearly 30 countries and regions with a global audience of over 700 million. The Tour culminates with the WTA Finals, honoring the season's top singles and doubles players based on the final standings of the Race to WTA Finals leaderboard. Further information on the WTA can be found at wtatennis.com. CONNECT WTA on Instagram, YouTube, and Facebook Marni On The Move Instagram, TikTok, LinkedIn, or YouTube Marni Salup on Instagram and Spotify SUBSCRIBE TO OUR NEWSLETTER Sign up for our weekly newsletter, The Download, for Marni on the Move updates, exclusive offers, invites to events, and exciting news! OFFERS AG1: DrinkAG1.com/MarniOnTheMove DeltaG: Get 20% off deltaG Ketones today at www.deltagketones.com use our code Marni20 SUPPORT THE PODCAST Leave us a review on Apple. It's easy, scroll through the episode list on your podcast app, click on five stars, click on leave a review, and share what you love about the conversations you're listening to. Tell your friends to what you love on social. Screenshot or share directly from our stories the episode you're listening to, tag us and the guests, and use our new Marni on the Move Giphy!

Earnings season continues in the medical device industry. Hologic posted its Q3 results this week, and it was a mixed bag. Investors and analysts have questions about future margins. Fast Five hosts Sean Whooley and Danielle Kirsh review the company's performance and the analysts' views.  The FDA recently granted expanded indication to Teleflex's QuikClot Control+ hemostatic device. The expanded indication may allow Teleflex to target new clinical applications. Find out what the expanded indication covers, how it increases the device's versatility in treating different patient populations, and what executives say.  Abbott FreeStyle Libre 3 reader is now available and is covered by Medicare. The Fast Five hosts discuss how the FreeStyle Libre 3 reader works and how it pairs with Abbott's latest continuous glucose monitoring sensor. Gain insights into Abbott's pipeline activity and plans for the second half of 2023. Integra Lifesciences plans to resume manufacturing at its Boston facility just two months after it voluntarily recalled all tissue-related products made at the plant. Whooley explains why the company stopped manufacturing and how it has addressed the problems since the recalls, including the measures taken to strengthen leadership and project management.  The FDA has labeled Baxter's recall of some infusion pumps as Class I, the most serious kind. Kirsh and Whooley go over the issues behind the recall, how many devices are included and what resolution the company is offering.  Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.

Ariel Sutton, general manager of Imperative Care's stroke business, joins us to explain why she swapped her medical school dreams for the opportunity to wear steel-toed boots and a hard hat as an engineer. Sutton ultimately would marry her love of medicine with her passion for engineering and built a career helping medical device companies of many sizes to build successful programs. Now she's leading one of the fastest growing neurovascular businesses in the industry. In her new role she's going to help guide Imperative Care's plans to target stroke from many different directions, including surgical robotics. Learn more about Imperative Care here. https://imperativecare.com/zoom-stroke-solution/ This week's episode is sponsored by DeviceTalks West. Registration opens later next week. Go to DeviceTalks.com. Co-hosts Chris Newmarker and Tom Salemi review this week's Newmarker's Newsmakers including iRhythm, Medtronic, Illumina, Hologic, Senseonics, and Know Labs. Thanks for listening to this episode of the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network on any major podcast application.

Moon Surgical, a promising player in the field of surgical robotics, has successfully raised $55.4 million in funding to support the development of its surgical robot platform. This significant investment indicates growing confidence in Moon Surgical's technology and its potential to revolutionize surgical procedures. Fast Five hosts Sean Whooley and Danielle Kirsh discuss the company's technology and what those new funds are earmarked for.  In a creative and impactful move, Hologic has partnered with Eagles rookie Kelee Ringo and his mom to raise awareness about the importance of mammograms. This collaboration sheds light on the critical role of regular mammograms in the early detection and prevention of breast cancer. Whooley explains the details of the partnership, as well as the numerous other partnerships Hologic has engaged in to promote women's health and wellness. An independent study has provided further validation for Edwards' aortic valve with Resilia tissue. The study's findings underscore the potential of this technology to improve patient outcomes and contribute to the advancement of aortic valve therapies. Whooley details the study and the key findings in today's Fast Five episode.  Abbott has recently reported positive data for its TriClip Transcatheter Edge-to-Edge Repair (TEER) system. The positive data highlights the effectiveness and safety of the TriClip system, providing new hope for patients in need of mitral valve repair. Kirsh and Whooley explore the study's findings and how optimistic leaders at the company are. Precision Lens and its owner have been hit with a substantial $487 million judgment in a kickbacks case. This case highlights the importance of ethical business practices within the medical device industry. Whooley has all the details of the judgment and the judge's verdict on the case.  Check out the show notes at MassDevice.com/podcast.

In the Heroncode studio we are joined by the Managing Director, MEA at Hologic, Inc, Sarah Kaouache.Sarah Kaouache holds a doctorate in pharmacy and an MBA in healthcare strategy and marketing. She has built her career in the last 15 years in the healthcare industry within multinational companies both in the pharmaceutical and medical device sectors, such as Allergan, Cynosure, and most recently Hologic, a global medical device company championing women's health.She is an agile, resilient, and inclusive leader with proven success across various fields such as ophthalmology, transplants, dermatology and within diverse geographies managing Europe, Middle East and Africa. Her innate curiosity, passion for learning, and ability to overcome challenges have subsequently defined her life and career journey.For more information visit Heroncode.com Hosted on Acast. See acast.com/privacy for more information.

Si je vous dit ménorragie, qu'est ce que ça vous évoque ? Pour la majorité des personnes, pas grand chose. et pourtant ce syndrome touche 20 à 30% des femmes en âge de procréer en France. Tout au long de leur vie, les femmes peuvent être exposées à la survenue de règles abondantes, en particulier les femmes présentant une maladie hémorragique héréditaire. Véritable enjeu de santé publique, les règles abondantes peuvent être la conséquence de pathologies multiples. Un enjeu public certes, mais dont on n'entend pas beaucoup parler, et qu'on diagnostique peu.  Alice souffre de ménorragie depuis ses 13 ans : des règles très abondantes qui handicapent son quotidien. Fatigue extrême, anémie, cycle irrégulier, gêne, honte, douleur… Alice cherche par tous les moyens une solution miracle, autre que la pilule, qui soulagerait ses règles abondantes. Un sujet encore trop tabou et méconnu par conséquent.  Je laisse Alice vous raconter son histoire et je vous souhaite une très bonne écoute.  Pour aider les femmes à réaliser leur diagnostic et à s'informer sur les règles abondantes, un site internet très complet www.regles-abondantes.fr a été créé par la société Hologic, leader mondial dans le traitement chirurgical des règles anormalement abondantes.   Ne rate plus rien ❤️ Retrouve Hystériques sur Instagram   Découvre mon compte personnel  Participe à mes retraite de yoga 

Marissa Fayer is a 20-plus-year medtech executive, innovator, entrepreneur, investor, and philanthropist. In this episode, Marissa discusses her deep passion for furthering women's healthcare, the trip to Costa Rica that changed the course of her career trajectory, and the fact that before she was recruited into healthcare, she was on track to become an aerospace engineer.  Guest links: http://www.marissafayer.com/ | https://www.herhealtheq.org/  | https://www.ggventures.co.uk/ Charity supported: Feeding America Interested in being a guest on the show or have feedback to share? Email us at podcast@velentium.com.  PRODUCTION CREDITS Host: Lindsey Dinneen Editor: Tim Oliphant Producer: Velentium   SHOW TRANSCRIPT Episode 004 - Marissa Fayer Lindsey Dinneen: Hi, I'm Lindsey with Velentium and I'm talking with MedTech industry leaders on how they change lives for a better world. Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello and welcome to the Leading Difference Podcast. I'm your host Lindsey, and I am excited to introduce you to my guest today, Marissa Fayer. Marissa is a 20 plus MedTech executive, innovator, entrepreneur, investor, and philanthropist. She is the CEO and founder of nonprofit, HERhealthEQ, the CEO of DeepLook Medical, VP of Operations at Ultrasound AI, and the US Partner at Goddess Gaia Ventures. Her mission is to move innovation and the health of women forward throughout the world. Okay, obviously an amazing person. Marissa, thank you so much for joining us today. Marissa Fayer: My pleasure, thanks so much for having me. Lindsey Dinneen: I literally read your bio and thought, "Oh my goodness. Do you sleep?" Marissa Fayer: Unfortunately, not very much, but it's not as a result of work probably. My brain never shuts down. There's a lot to do in women's health, so gotta keep going. Lindsey Dinneen: Yeah, absolutely. I would love to learn a little bit about your background, how you first got intrigued in this field. Just tell me a little bit of your backstory, if you don't mind. Marissa Fayer: Yeah, for sure. I wish I can say that it was interesting, but unfortunately it's not. I didn't really have any intentions in going into healthcare. I was luckily recruited into it straight out of university. I originally wanted to go into aerospace, but when I was graduating from BU, from the engineering school, it was a downturn in aerospace, and thankfully a healthcare company offered me an amazing position. So, I went straight into healthcare and as the saying goes, "once you go into healthcare, you never leave." Thank God, because I realized it was my mission, my passion. And then thankfully I also joined the largest women's health company in the world and really realized that was my mission and my passion. So it was all meant to be, but my career was 15 years in corporate, working for large medical device companies, developing new products, working in operations and manufacturing, and handling a lot of mergers and acquisitions. And after 15 years, just decided to make a change and I think it was probably as a result of some burnout. And for the last nine years, I've been consulting and built a very successful consulting practice helping small to mid-size companies scale and grow and figure out their operations and their manufacturing, but especially their business strategy and what is interesting to them. And I've been very strategically focusing on companies that are affecting women and women's health. And I've been in the women's health space really before people honestly knew what it was. And so, it was always my passion. I was always really interested in women in STEM and as a woman in STEM, that was super interesting to me. But I also realized after living abroad in Latin America that having schools wasn't the issue. It was ensuring that girls going to school was the issue, and girls weren't going to school because their mothers and their grandmothers and their aunts were not healthy. And that was a problem as an engineer that I could fix. And so, it's been quite the journey. And MedTech and healthcare-- I'm biased, I feel like it's the best industry to be in. You're doing something great, you're giving back to society. And it's also, let's be clear, lucrative, this is not a nonprofit industry. This is a lucrative industry. Lots of innovation happening, lots of exciting news happening. And so I think it's the best place to be, but you know, obviously I'm biased because it's been 23 years. Lindsey Dinneen: Sure. Well, I think you've earned the bias, right? So you mentioned, having had a passion for women's healthcare for a very long time, and thank goodness for you because we need way more of that. Thank you for being that advocate and being on the forefront of that. I am curious-- you mentioned a couple different things playing into that passion when you were growing up. Was that something that you were aware of maybe even before college as being a need or an interest of yours? Marissa Fayer: Yeah. I grew up in a fabulous house and a fabulous family and we were always supported in whatever we wanted to do. I went to space camp twice, like I was training to become an astronaut and an aerospace engineer. There was no limit to a girl in our family. There was no limit to anybody. And we were in a position to be lucky, and I'm very cognizant of that to be fortunate, to be able to have those opportunities. But I went to space camp twice as a kid. I studied math and science. That was my pathway even in elementary school and middle school and high school. That was my pathway. I went to engineering school. That was not incredibly common 25 years ago especially from a girl from New York. And so again I'm incredibly lucky and I know that most people don't have all of this opportunity. But I did not grow up in a society or in a family that said you can't do that. So I didn't grow up with those misconceptions. And so when I go somewhere and they're like, well, this girl can't go to school. To me, that's not acceptable because that was never acceptable to me. I mean, what kid literally goes to college still thinking they're gonna be potentially an astronaut. I mean, there's very few. I literally enrolled in aerospace engineering. And graduated with a different engineering degree, But that was the path I was pursuing. And, and it was supported the entire time and, and trust me, I've put my deposits down. I'm hopefully still going, but, but in a different capacity. Lindsey Dinneen: Yes. That's amazing. What a story! Do you think that your interest in aerospace engineering and your, education in that field-- has that played a particular role? Has it carried over in any way to the medtech side of things? Marissa Fayer: Listen, going down a semi nontraditional pathway, so as an engineer you're always curious, I always had that curiosity mind. So, whether you're an engineer or an astronaut or any of those, I was very curious about how things worked or how to make it better and how to make it efficient and things like that. So, that plays into all of it. There was also a societal element. I like to explore. Part of exploration is making things better and bringing things back to make things better here. So my intent with healthcare is to make things better. I think that's most everybody's intent with healthcare, at least the good people. So certainly I think it does play over. I was curious, I wanted to explore and I wanted to make things better. And so I think that played a significant role in staying in healthcare as well. And listen, I always wanted to do something for society. I thought it was gonna be through space exploration. And it turned into, it's actually through improving women's lives and health throughout the world. Lindsey Dinneen: Yeah. And I love that you highlight that because that, I think that's a really important thing that doesn't get talked about enough-- that it is okay to pivot and to change what you originally expected to do. Because sometimes those non-traditional pathways do, like you said, give you a different perspective and different insight than maybe somebody who has always been on that path. So, yeah, there's a lot of value to that. Marissa Fayer: We're not in a society anymore, that you have to do the same thing for 50 years. And there's so much interconnectivity and there is so much learning that happens cross industry that is so helpful and applicable to help each other industry. So let's just take, cuz we're talking about health and health tech. The tech industry, in so many ways is ahead of the health industry. But to apply some of the tech learnings into the health industry to help accelerate health tech, that's important. So that's just like one singular example of how industries can cross over and how it's gonna benefit us in multiple ways. Lindsey Dinneen: Yes. Absolutely. Is there a particular moment that stands out to you because it clearly confirmed that this was the right career for you or any sort of defining catalyst moment where you thought, "Yes, this is it?" Marissa Fayer: that's a great question. When I think back to it, I think it was when I formed HERhealthEQ and realized that I could help women and women's lives very specifically using the knowledge that I gained through industry and applying it on a global perspective. And the fact that it doesn't even matter how much we scale. And while I have a grand ambition by the end of 2025 for us as an organization to impact the lives of a million women-- and we are on track to do that-- but that almost doesn't matter because it matters to the one person, the one woman that we have impacted and improved her life because it matters to her family, it matters to her. And I sometimes have to think about it. So when I started the organization, I didn't have those lofty goals. I just wanted to do something good and wanted to help because I saw that there was a gap, and repurposing medical equipment that is completely usable and getting it to regions and doctors and clinics that need it. That is important and that saves lives. And so for me, every time we hear a story or every time, we get our impact numbers back or anytime I think about that one woman being able to go home because potentially a cancer was caught really early as opposed to it being caught at stage four where it's non-treatable, she's able to walk back into her house and do whatever she wants to do because it was caught early and it was able to be treated. Every time it happens, that's when I realize, that is probably the moment. And I guess they just keep on coming, but the first time that hit me --that was, that was the moment. Lindsey Dinneen: That's really powerful. Thank you for sharing that. And in your role now, I know it is one of leadership, and I am curious how you would personally define leadership or what does leadership mean to you? Marissa Fayer: I'm more of a "lead by example," and a "walk the walk," "do the do" kind of, leader. I, I trust people who I work with. And I don't think that any leader should work with people they don't trust. And listen, there's always instances where things have to be worked on. And I'm not naive, certainly, and I have plenty of my own instances that have to be worked through, but it's more-- you have to work with people and assume that they're going to do the job, and you have to assume that they want to, and they have to be incentivized to be doing that. So, I lead by example. I work hard. I meet my commitments. I do what I say and people see that. If I wasn't meeting any of my deadlines or I wasn't doing what I was saying, then everyone would understand that's acceptable. And I also have to hold people accountable to their actions as well. So from my perspective, it's very much a lead by example mentality. And that's far more effective than the" iron rule", the very micromanage, tell me exactly every minute what you're doing. And listen, people have different ways of working as well and different needs and styles of working. And I was always one of those. And so I'm very cognizant that people have different work speeds. Listen, there has to be deadlines that are set and deadlines that are achieved and things like that. But you also have to let people work when it is the best time to get their genius. Not everybody's a morning person. Some people are evening people, some people work better on a weekend. You have to be flexible enough within the timeframe that you have to be able to work within each person's level of genius and zone of genius. Because it differs for everybody and, and also people have life. And life happens. And I think being a human is really helpful. And it's so basic, honestly, but like really just being a normal, nice human is really genuinely helpful. And I think people just need to remember that. Lindsey Dinneen: Yeah, great advice. And speaking of advice, what is your best piece of advice for someone interested in obtaining a leadership role within the medtech industry? And I'm specifically interested because of your focus on women and women's healthcare. What about a woman who is particularly interested but might feel daunted by that? Marissa Fayer: Yeah, ask for it. Actually, demand it, but ask for it. Because if you don't ask, you're never gonna get it. So ask. People aren't gonna know that you want it, it's not ESP. They're not gonna read your mind. Ask them, talk to them about it. Tell people that you want a leadership position. Go after it! There is this silly misconception like, "Oh, you're gonna be seen as bossy." No. Good, good. You should be. Go after what you want. And if you are working in an organization where that is not encouraged, that's not the right organization for you. There are plenty of organizations out there that encourage that. I'm not saying do it rudely. I'm saying work with people. And it doesn't necessarily have to be your direct manager, either. Work with people in your organization and tell them what you want. You can ask their opinions, but you can also tell them what you want. You want a management's position? Ask their advice on how to get there and then follow their advice on how to get there. Because then you can go back to them and say, "Thank you for your advice. I have followed it. Now it's time for me to become this position." And there is irrefutable evidence for you to get that position. So, just do it. Ask for it, demand it, but do the work. I come from a generation where you still have to do the work. It is not automatically given to you because you've been somewhere for two years. Do the work and earn it because, first of all you'll feel better about yourself and second of all, you'll learn more, and you'll go further in the long run, and that's more important. It's not this next tiny milestone, it's the future. So if you have done the work and you've learned, you've set yourself up for the future, but really just ask for it and ask and communicate what you're looking for because nobody is naturally-- or very few people are naturally-- just going to give something to you without you asking. Lindsey Dinneen: I love that advice. I was smiling and nodding my head the whole time because I hundred percent agree with you. And also it is one of those things where if you don't ask, the answer is always "no". Very few times, are you just gonna be handed something, so. Brilliant. Love it. And how do you prioritize your own continued learning and growing as a leader? Marissa Fayer: Yeah, it's a lot of listening, you know, a lot of book reading. Thank God for podcasts. I'm a podcast on the go listener, so that's great. I, I listen to a lot of people in a lot of different industries as well, cuz I think that's really important because you can learn from other industries and learn from other different styles. So generally it's listening to feedback from others. I don't necessarily take everybody's advice because advice is a dime a dozen. You have to figure out what to do with it. But I listen, hear what people are saying. I listen to also direct feedback. I listen for trends in the market and understanding what's up and coming as well, and and trying to prioritize those and hopefully trying to be ahead of the curve a little bit. But I think the key to learning regardless of what stage you're in again is just about, listening and absorbing. Lindsey Dinneen: Yeah, absolutely. So you mentioned back at the beginning when you were telling us a little bit about your background of spending some time in Latin America and how that helped influence the way that you would eventually start your own business, and your perspective on women's healthcare and whatnot. I'm curious if you would be willing to elaborate a little bit more on that time that you had there and its impact on what you do now. Marissa Fayer: I mean, besides the fun, the hiking, and the surfing and friends and, all that stuff, I worked very hard. I went to a country where I didn't speak the language and I had to learn it after work. It was a great learning experience. And that's the other part of like continuous learning. Like you always have to do something different. For me, Costa Rica fully shifted who I was. And it created my future. I went there with a large multinational. I was integrating an acquisition. I was integrating other acquisitions into that, company and I was talking to a friend and women were dying of breast cancer at alarming rates because the one mammography machine in that region broke down. And of course I thought that was ridiculous because I just, right before moving to Costa Rica, deployed the 3D mammography systems, and I knew the 2D systems were always coming back and they were lined up against the warehouse wall, and they were just sitting there. And so I knew that there was no reason for women to be dying because they didn't have a mammography machine. I literally had them lined up against a warehouse. Like why wouldn't we just ship one down, you know, as a donation. So, going through that entire process and creating an entire program to give back to the countries which medical device companies are working in and other industries are working in, it shifted my mindset on how for-profits and nonprofits can work together. And it was the origin story for the beginning of HERhealthEQ. And I didn't start it originally at that time I waited until I left corporate. For years I had to formulate my thought around it. I had to build a successful consulting firm first and all of these things. But that time formed who I am right now. Between teaching you how to work and live in another country and figuring everything out yourself. And also more or less finding your life and your passion all in the same three year timeframe is pretty spectacular. So 10 years later the mammography machine is still working, it's still screening women in Costa Rica. And now that same company, Hologic, has supported a HERhealthEQ program for the screening of cervical cancer in Costa Rica. So it's come full circle 10 years later, which is incredible. That's kind of unheard of. And it's so special and spectacular. So, to say the least, Costa Rica certainly changed my life. Lindsey Dinneen: That's an amazing story. Marissa Fayer: You just never know. And that's the point. I didn't go to Costa Rica thinking "I wanna life change and I gotta change everything here." I went to work. I had never thought about leaving corporate. I never thought about starting a nonprofit. I never thought about becoming a consultant. I never thought about these things. These were not in my life plans. And so I think you just generally have to be open to understand and receive what the universe is like literally putting in front of your face. If the aerospace industry was not tanking in 1999, in 2000, I could be at NASA right now. I mean, who knows? But I think that being in Costa Rica, lining up those circumstances, everything that I learned put me in that position to open my eyes, to see that as an engineer in a healthcare company, in a medtech company focused on women's health. That's why it changed my life. Because I saw an opportunity, I saw it, and I acted. Lindsey Dinneen: Yeah. I really appreciate that perspective of being open to things that you really probably would never have expected. Like you said, you didn't go there thinking, "Oh, this will be the impetus for me to have this amazing organization one day." That wasn't the plan, but what you did do is you went with this willingness to explore, and that led you to an incredible opportunity to really help people. So I really like that piece of advice as well. So imagine someone were to offer you a million dollars to teach a masterclass on anything you want. It does not necessarily have to be in your industry. What would you choose to teach and why? Marissa Fayer: First of all, let's just be clear, I would put the million dollars back into charity and I wouldn't be pocketing that. I think I would love to teach. I would love to be paid a million dollars for it. But I would also like to channel that money actually to do the work, less to hear myself speak. So, putting that big caveat out there. But what I would love to teach would be how can nonprofits and for-profits partner or better partner together to, to better the world? So how can they work together to better life, better the world? And, and obviously very specifically for me, women's health. But just generally the world. Nonprofits seem to be working in this one vertical, for-profits work in this other vertical. There is now a lot of thankfully overlap. There's just not enough. And for-profits have the power to catalyze change. Nonprofits with for-profits are the way oftentimes to do that, and social enterprise-- I'm considering both of those in the mix-- but to really have them work together to change the world and better the world. That is how to mix profit and purpose. That's what I would love to teach on and also take that class. So, any recommendations on if that class exists? I would love to be learning about that a lot more. . Cause we do it. But it's still a continuous learning journey and I think that it's something that everybody still needs to get better at. There's not any one organization, not even the largest in the world, and not even the largest nonprofits and largest corporations that are good at this. Nobody has it down, and I don't think it should be a formula. I just think it needs to be better communicated. So I would love to teach a class on that once I figure it out. That's the next edition of our podcast, I guess? Lindsey Dinneen: Right? Okay. So brilliant. So we'll have you back on, once you have this masterclass that you can teach us, that'd be amazing. Marissa Fayer: Yes. I might be 90, so we'll see. Let's hope not. Lindsey Dinneen: Well, amazing. And to that point, is there a good way that for-profit organizations can partner with you and what you are doing to create some change and to help each other? Is that something that you are currently actively seeking help with? And how could an interested company do that? Marissa Fayer: We are a thousand percent actively searching and looking to work with any type of corporation, doesn't necessarily even have to be in the medtech or the healthcare space. I mean, obviously there is a linkage there. Let's just be clear. But, we're looking for like-minded organizations to partner with them, to support our work, but also to increase their CSR, their corporate social responsibility and their ESG and their DEI and all of those things that are important as a corporation and their employee engagement, et cetera, to promote that out in the world, because it is a corporate imperative for them to do that. We wanna be part of that corporate imperative. And so anyone can go to HERhealthEQ.org or email us at info@HERhealthEQ.org or find me at marissafayer.com. But it is the way to move things forward. So we are actively doing it right now, and we're seeing incredible results. We're screening 50,000 women in Costa Rica right now with a corporate partner. And that's per year. And that's as a result of three corporate partnerships. So it is the power to drastically improve lives with not a lot of money. So, yes, we're actively seeking them related to supporting women, supporting healthcare on a global scale. And, we look to partner with any type of organization. It could be the CSR department. It could be through a grant, it could be through a donation, it could be through an employee retention program. There's so many ways. It could be through even a marketing program that has been created jointly because, listen-- when we are able to do the work, those metrics and impact shared back to the companies and they're able to report and use them for their goodwill as well. And we want that, we want them to be proud of the work that they've sponsored and partnered with us for. That just amplifies us. It amplifies them and it amplifies the focus on improving women's health, which is the end goal for everything that I do and that we do. And that's how everybody can partner with us. Thank you for asking. So, yes, would love to partner with corporations however, large or small, there is no size limit. That's the other thing. Like small corporations are also incredibly applicable. Lindsey Dinneen: Excellent. Thank you for providing all of those resources too so we can get in touch with you. All right, so what is the one thing you wish to be remembered for after you leave this world? Marissa Fayer: That women deserve access to quality healthcare regardless of where she lives. That's it. Period. End of sentence. It is a requirement. Healthcare should be equal in access and equitable for everybody and that is currently not even close to being the state of where we are right now. And so, I'd love to be remembered after I leave this world for improving the situation and ensuring that women have better health and better access to healthcare. Lindsey Dinneen: And then final question, what's one thing that makes you smile every time you see or think about it? Marissa Fayer: On a personal level, obviously my niece and my nephew. Because that's, thank God, unconditional love, but I also think it's like the little things: a sunny, warm day in New York City in the middle of winter. I think given the crazy lives that we all have, I think taking tiny moments of joy are just so important, and I don't necessarily remember that every minute of every day, but I think it's worth taking just a moment every day to create joy or to appreciate joy. So I don't know what it is, it varies day by day. Some days it's a chai latte. Some days if I'm traveling in Europe, it could be a delicious croissant. Or it could just be a delightful walk. It could be anything. I guess whatever you're in the mood for to make you joyful that day. Lindsey Dinneen: I love it. Marissa Fayer: Yeah. Yeah, I know. It's very random, so I don't have a good, clear answer for you. So who knows? Lindsey Dinneen: You know what, something joyful is a beautiful answer because you're right, it can vary from day to day, and all those little things add up to make you smile. That's wonderful. Well, thank you so very much for joining us, for all of your amazing advice and insights. Really enjoyed getting to know you a little bit, getting to know your organization and of course, your passion behind it and why it is so important. So I really appreciate that, and we are honored to be making a donation on your behalf as a thank you for your time today to Feeding America, which works to end hunger in the United States by partnering with food banks, food pantries, and local food programs to bring food to people facing hunger, and it also advocates for policies that create long-term solutions to hunger. So Marissa, thank you again, so very much. We wish you just continued success as you work to change lives for a better world. Thank you for being here. Marissa Fayer: Thanks so much for having me. It was a pleasure. Lindsey Dinneen: Great, and thank you also to our listeners for tuning in and if you are feeling as inspired as I am right now, I'd love it if you'd share this episode with a colleague or two and we will catch you next time.  The Leading Difference podcast is brought to you by Velentium. Velentium is a contract design and manufacturing firm specializing in the development, production and post-market support of diagnostic and therapeutic active medical devices, including implantables and wearables for neuromodulation and other class three indications. Velentium's core competencies include electrical design, mechanical design, embedded software, mobile apps, contract manufacturing, embedded cybersecurity, OT cybersecurity, systems engineering, human factors and usability, and automated test systems. Velentium works with clients worldwide from startups seeking seed funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

While some of the technical action is improving in stocks, volume is strikingly missing. Hologic showed a breakout today with decreasing volume and Souther Copper and Alamos Gold got health bounces without volume.

Super STEM Saturday is a free science festival held on March 11, 2023, at California State University San Marcos. Daren Wade is the Director of General Atomics' Aeronautical Systems Integration Group (EIG) and has been involved with the event since 2010. Daren shares how the event engages young engineers and students curious about learning more about how the world works. General Atomics is an event sponsor along with ViaSat, Thermo Fisher Scientific, County of San Diego, Hologic, Encodia, Tri-City Medical Center, Nordson, CalSense, Cox Communications, The Difference Card, Erickson-Hall Construction, Kaiser Permanente, Pacific Western Bank, RBC Capital Markets, Stradling, Young, Minney & Corr, LLP, Cigna, North Island Credit Union, and HME. This free, rain-or-shine event is from 10:00 am-4:00 pm. Learn more here.View the event flyer here

Si je vous dit ménorragie, qu'est ce que ça vous évoque ? Pour la majorité des personnes, pas grand chose. et pourtant ce syndrome touche 20 à 30% des femmes en âge de procréer en France. Tout au long de leur vie, les femmes peuvent être exposées à la survenue de règles abondantes, en particulier les femmes présentant une maladie hémorragique héréditaire. Véritable enjeu de santé publique, les règles abondantes peuvent être la conséquence de pathologies multiples. Un enjeu public certes, mais dont on n'entend pas beaucoup parler, et qu'on diagnostique peu.  Alice souffre de ménorragie depuis ses 13 ans : des règles très abondantes qui handicapent son quotidien. Fatigue extrême, anémie, cycle irrégulier, gêne, honte, douleur… Alice cherche par tous les moyens une solution miracle, autre que la pilule, qui soulagerait ses règles abondantes. Un sujet encore trop tabou et méconnu par conséquent.  Je laisse Alice vous raconter son histoire et je vous souhaite une très bonne écoute.  Pour aider les femmes à réaliser leur diagnostic et à s'informer sur les règles abondantes, un site internet très complet www.regles-abondantes.fr a été créé par la société Hologic, leader mondial dans le traitement chirurgical des règles anormalement abondantes.   Pour contacter Alice  

Murthy Simhambhatla launched his medtech career during the epic race to develop groundbreaking drug-eluting stent technologies as a new approach to battling cardiovascular disease. Over two decades later, following a career that took him across the globe and clinical specialities, Simhambhatla finds himself involved in another exciting push to bring new technologies to bear on prevalent medical problems. Simhambhatla leads Setpoint Medical, a trail blazer in the neurostimulation space that's tapping the vagus nerve as way to battle inflammation. In this discussion, we'll cover Simhambhatla's career and how Setpoint is positioned for the future following a significant capital raise. Chris Newmarker, executive editor of life sciences at MassDevice shares his Newmarker's Newsmakers including Avonics, Invacare, Philips, Johnson & Johnson, 3M, Stryker, Edwards, Hologic, BD, Edwards, and Boston Scientific. Thanks for listening to the DeviceTalks Weekly Podcast. You can subscribe to the DeviceTalks Podcast Network on any major podcast player.

We begin today's show discussing Meta's latest earnings sending shares surging, with insight from our Julia Boorstin and Bernstein analyst Mark Shmulik. Then, Barclays Head of U.S. Equities Venu Krishna to discuss the Fed's latest rate hike, and we preview Apple's results after the bell with CNBC's Steve Kovach and Cowen Managing Director Krish Sankar. Later, our Julia Boorstin returns for a look at TikTok fighting back against regulatory scrutiny, and Hologic CEO Stephen MacMillan joins after the medtech company beat the Street in Q4.

I veckans extra avsnitt gästas jag av gynekologen och förlossningsläkaren Helena Graflund Lagercrantz för att prata om varför vi får livmoderhalscancer, hur vi kan upptäcka i tid via screening och om vaccination. Screening och vaccination tillsammans gör att denna cancerform kan utrotas inom kort. Det är Hologic som är sponsor av detta avsnitt för att belysa vikten av att vi gör screening och för att färre kvinnor ska drabbas och att vi tillslut ska besegra livmoderhalscancer. Hologic är ett innovativt medicintekniskt bolag som fokuserar på att förbättra kvinnors hälsa genom tidig upptäckt och behandling. Företaget är en världsledande utvecklare, tillverkare och leverantör av högkvalitativa produkter inom diagnostik, brösthälsa, gynekologisk kirurgi och skeletthälsa. Gå in på hologic.com för att läsa mer! Missa inte veckans viktiga extra avsnitt. Producerat av @kaspersen_nyfikenpa @perfectdaymedia

Kurt interviews Tom Livingston, Director of Field Marketing and Learning and Development at Hologic, a medical technology company focused on women's health. Tom discusses the importance of concise, patient-centric messaging, and tells Kurt about Hologic's new hire and leadership training programs.

The 2022 WTA season had everything: a 37-match win streak, the retirements of the current #1 (abrupt) and the GOAT (expected), a Wimbledon with no ranking points, and a major drug suspension. Iga Swiatek's dominance didn't leave much room for her competitors, but other highlights included Ons Jabeur's steady rise to world #2 and two Slam runner-up finishes, Caroline Garcia's singles renaissance and WTA Finals title, and utter doubles dominance from Krejcikova/Siniakova. We've also got some juicy listener-generated “things you loved/hated” content and the kind of typically bizarre moments that keep us coming back every year.    Plus, we've just launched our GoFundMe - please read a bit about we do and donate if you can!      0:30 Announcing our GoFundMe 2022 and reiterating our mission 6:05 Three key moments: Ash's Australian win + retirement, Iga's win streak, and Serena's evolution 11:00 The other major stories: the instability at the top for everyone but Iga, Simona Halep's remarkably odd year, and the total breakdown of COVID protocols 18:40 Starting the year with Barty as the undisputed #1 25:20 Ash's retirement coincides with the start of Iga's 37-match win streak  34:45 Grass season: Serena dominates the conversation from Eastbourne to the US Open; Rybakina wins the points-less Wimbledon  42:00 Summer hardcourt stretch: our own return to live tennis; Halep & Garcia grab titles but Swiatek restores order in New York 54:55 Discussing the WTA year-end award nominees 60:45 Our own picks for 2022 breakout players - how'd we do? 63:25 Remember when? A broken necklace, a broken doubles team, and Ostapenko's ... everything 72:45 Things you loved about WTA tennis in 2022 81:50 Things you loathed in 2022: no points at Wimbledon, no more business buns 85:55 The WTA's finances: Hologic sponsorship and a potential deal with private equity 

The Dow surged over 700 points, with all three averages starting Q4 with strong gains, and Jim Cramer is laying out what drove the market higher and if the market's fundamentals can keep the rally going. Then, as Breast Cancer Awareness month kicks off, Cramer sits down with women's health company Hologic. Then, Cramer's digging deeper into recent IPO Permian Resources to see if this Permian basin play could bring profits to your portfolio. Plus, Cramer's exclusive with Agua Media CEO Rick Sanchez.

On the first episode of Season 2 of The Game-Changing Women of Healthcare, Meg Escobosa is joined by Eileen Maus, CEO of Renovia Inc.Meg and Eileen discuss the inspiration for Eileen's passion for women's health, starting a career in healthcare in the 80's and 90's, and the truth about urinary incontinence and its stigmatization. They also talk about the unique benefits of digital therapeutics compared to traditional therapies, how Covid drove a major innovation in Renovia's approach to clinical trials, the unique benefits of a women-led organization, and optimism's role in entrepreneurship and innovation.-----------Eileen Maus, CEO of Renovia, Inc., brings 20 years of healthcare experience to Renovia, a women-led company developing digital therapeutics for women's pelvic floor disorders. Renovia's flagship product, the leva® Pelvic Health System, is an FDA-cleared prescription device that can help women strengthen their pelvic floor muscles effectively to treat stress, mixed, and urgency urinary incontinence, including overactive bladder.Eileen grew her passion for women's health at CYTYC Corporation, which is now Hologic, where as Vice President of Commercial Operations in the Surgical Division, she was a key contributor to its rapid growth from $8 to $700 million. Eileen also served as chief commercial officer for Constitutional Medical Investors, a portfolio company of Warburg Pincus. She received her Bachelor of Science degree from LaSalle University in Philadelphia, PA.Further Reading:Renovia Inc.Leva®Digital Therapeutics AllianceHologicNovasureThinprep Pap Smear-----------The Game-Changing Women of Healthcare is a production of The Krinsky Company. Hosted by Meg Escobosa. Produced by Meg Escobosa, Calvin Marty, Chelsea Ho, and Wendy Nielsen.Edited, engineered, and mixed by Calvin Marty. Theme music composed and performed by Calvin Marty. ©2022 The Krinsky Company

With so many geopolitical events affecting tennis, it's a timely moment for Catherine to speak at length to WTA CEO Steve Simon. Following yesterday's interview with Pam Shriver, and the decision of Wimbledon and the LTA to ban Russian and Belarusian players, Catherine starts by asking him about those urgent issues. Later, there's discussion about the WTA's decision to pull out of China, Tennis United, the latest on Peng Shuai, new title sponsor Hologic, on court coaching, and the best of 3 vs best of 5 debate at Grand Slams.Sign up to our newsletter - https://bit.ly/TennisPodcastNewsletterFollow us on:Instagram - www.instagram/thetennispodcastTwitter - www.twitter.com/tennispodcastFRIENDS OF THE TENNIS PODCAST Friends of The Tennis Podcast receive exclusive access to bonus podcasts throughout the year and help to keep the weekly podcast and the Grand Slam dailies free-to-all. So far in 2022, we've produced two episodes of Australian Open Re-Lived, an Australian Open review show, three listener Q&A's, and a special 100-minute show dedicated to the career of Juan Martin del Potro. Become a Friend - https://bit.ly/FriendOfTheTennisPodcast See acast.com/privacy for privacy and opt-out information.

Most people don't look forward to heading into their doctor's office, or their annual OBGYN exam. Office spaces are often sterile environments, that aren't exactly welcoming. But what if your OBGYN office offered yoga, ayurvedic wellness, nutrition, and more in a calm and pleasant environment. As a healthcare expert, Dr. Shepherd strives to educate people on how to address their physical, sexual, and emotional health. She currently sits on the advisory boards for Ro Medicine, Women's Health Magazine, Abbvie, Myovant, Responsum, Hologic, and HealthyWomen.org. In her Dallas practice, she works with a team of therapists, yoga instructors, Ayurvedic wellness coaches, nutritionists, exercise specialists, and other health professionals dedicated to women's health.Jessica Shepherd MD, MBA, FACOG, is a board-certified OB-GYN and the Chief Medical Officer for Verywell Health. She is the founder and CEO of Sanctum Med + Wellness, a wellness concierge practice, and is affiliated with Baylor University Medical Center in Dallas, Texas.Dr. Shepherd sits down with Dr. Pam to talk about menopause, creating a safe and comforting space for annual OBGYN visits, and how we can continue to make women's health care better, consistent and reliable.

As a gynecologist, our guest Dr. Jessica Shepherd has talked with women about their health issues over the last ten years.Most people don't look forward to heading into their doctor's office, or their annual OBGYN exam. Office spaces are often sterile environments, that aren't exactly welcoming. But what if your OBGYN office offered yoga, ayurvedic wellness, nutrition, and more in a calm and pleasant environment. As a healthcare expert, Dr. Shepherd strives to educate people on how to address their physical, sexual, and emotional health. She currently sits on the advisory boards for Ro Medicine, Women's Health Magazine, Abbvie, Myovant, Responsum, Hologic, and HealthyWomen.org. In her Dallas practice, she works with a team of therapists, yoga instructors, Ayurvedic wellness coaches, nutritionists, exercise specialists, and other health professionals dedicated to women's health.Jessica Shepherd MD, MBA, FACOG, is a board-certified OB-GYN and the Chief Medical Officer for Verywell Health. She is the founder and CEO of Sanctum Med + Wellness, a wellness concierge practice, and is affiliated with Baylor University Medical Center in Dallas, Texas.Dr. Shepherd sits down with Dr. Pam to talk about menopause, creating a safe and comforting space for annual OBGYN visits, and how we can continue to make women's health care better, consistent and reliable.

Willkommen zur neuen Ausgabe von Chip & Charge dieses Mal mit der großen Rückschau auf Indian Wells und ein paar News aus der Tenniswelt. Swiatek im Finale souverän Bei den Damen konnte sich am Ende Iga Swiatek in der Wüste durchsetzen. Für die Polin war dies schon der zweite große Titel des Jahres, nachdem sie sich im Februar beim 1000er-Turnier in Doha ebenfalls zur Siegerin krönen konnte. Auch in der Weltrangliste macht Swiatek einen weiteren Sprung, wird dort mittlerweile auf Platz 2 geführt. Ihre Finalgegnerin hat sich in der Weltrangliste nach oben gearbeitet denn für Maria Sakkari geht es nun auf Platz 3. Die Griechin, die sich in den letzten 12 Monaten als Top 10 Spielerin etabliert hat, jedoch im Ruf stand keine großen Finals zu erreichen, konnte hier erstmals bei einem 1000er-Turnier das Endspiel erreichen. Ebenfalls in Wüste überzeugen konnten Simona Halep und Paula Badosa, die es ins Halbfinale schafften. Für Naomi Osaka gab es hingegen wieder eine frühe Niederlage. Fritz stoppt die Siegesserie von Nadal Bei den Herren konnte sich Taylor Fritz seinen ersten großen Titel sichern. Der Amerikaner setzte sich im Endspiel gegen Rafael Nadal durch. Nadal hatte dabei in den vorherigen Runden besonders intensive Matches gegen Nick Kyrgios und Carlos Alcaraz bestritten. Alcaraz ist immer noch auf dem Weg nach oben, überzeugte auch hier in Indian Wells durch weitestgehend komplette Leistungen, doch Nadal erwies sich als zu große Hürde. Während es Daniil Medvedev, Stefanos Tsitsipas und Alexander Zverev nicht über die ersten Runden hinausschafften, konnte Andrey Rublev seine konstante Form mit in die Wüste nehmen. Er erreichte das Halbfinale und verlor dort gegen Taylor Fritz. In den News blicken Andreas und Philipp auf den Davis Cup. Hier ist Hamburg einer der Austragungsorte der Gruppenphase. Zudem haben die Grand Slams eine Vereinheitlichung der Regeln für den Entscheidungssatz beschlossen. Andreas und Philipp stellen die neue Regelung vor, die ab nun bei allen Grand Slam Turnieren gelten wird.

On the show this week, International Paralympic Committee (IPC) president Andrew Parsons delivered a fiery anti-war message at the Paralympics opening ceremony — but it was censored in China. He also flubbed a line, for which the IPC has apologized, yet China has not even acknowledged its own censorship (1:40). International sporting bodies such as the IOC and FIFA have been awarding events to countries that create headaches. Is this era coming to an end (4:26)? The IPC has historically stood apart from the IOC, often taking a stronger stance on issues (5:10), but one difference at these two Games is that the Paralympics has fewer foreign journalists in the bubble asking the difficult questions (7:15). Was the IPC's decision to send Russian and Belarusian athletes home the right one? A Russian legal appeal could have resulted in a very messy situation (8:08). Do these and other sporting sanctions actually have any impact on Putin and the war (10:45)? The absence of Russian and Belarusian athletes has severely affected the medal standings, to China's great advantage (12:27), so does that impact the legitimacy of the results (14:45)? The weather in the mountains is still treacherous, with one skier blown off course by high winds, sustaining serious injuries and still only just missing out on a medal (15:30). Mark highlights the inspirational comments of Swedish athlete Ebba Aarsjoe (16:15), as well as the heartwarming back story of pro-basketball-player-turned-Paralympic-legend Li Duan, who was the final torchbearer at the opening ceremony (18:12).The Women's Tennis Association (WTA) announced a new title sponsor this week, further evidence that they could be moving on from China. What does that mean for other sports leagues — especially the men's tour, the ATP (20:22)? Guess who won the first tournament under new sponsor Hologic, who specifically referenced the WTA's Peng Shuai stance as a catalyst for their partnership? China's Zhang Shuai — who beat a Ukrainian opponent to win her third WTA title (23:58). Finally, swimmer Sun Yang's second appeal of a doping ban at a court in Switzerland was denied. Could this spell the end of his storied career (25:28)? See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The tennis news keeps coming, meaning Catherine, David and Matt have a lot to discuss, including: The WTA's new title sponsor - Hologic - and how it came about from the tour's stance on Peng Shuai and ChinaThe inspirational run of Dayana Yastremska in Lyon just days after she fled Ukraine with her younger sisterThe governing bodies' swift action to stop Russian and Belarusian players from competing under their national flag following a statement from Elina SvitolinaAn absorbing Monterrey final between Leylah Fernandez and Camila Osorio in which both players displayed their best selvesA round up of all the results from this weekend's Davis Cup Qualifiers Djokovic and Vajda split…again, Murray and Lendl get back together…againAsh Barty and Dominic Thiem to miss Indian Wells and Miami An update on Roger Federer's rehab and comeback plansSign up to our newsletter - https://bit.ly/TennisPodcastNewsletterFollow us on:Instagram - www.instagram/thetennispodcastTwitter - www.twitter.com/tennispodcastFRIENDS OF THE TENNIS PODCAST Friends of The Tennis Podcast receive exclusive access to bonus podcasts throughout the year and help to keep the weekly podcast and the Grand Slam dailies free-to-all. So far in 2022, we've produced two episodes of Australian Open Re-Lived, an Australian Open review show, a listener Q&A, and a special 100-minute show dedicated to the career of Juan Martin del Potro. Become a Friend - https://bit.ly/FriendOfTheTennisPodcast See acast.com/privacy for privacy and opt-out information.

Willkommen zur neuen Ausgabe von Chip & Charge dieses Mal mit Turnieren bei den Damen, dem Davis Cup bei den Herren und reichlich News. Yastremska bleibt Happy End verwehrt Andreas und Philipp fangen mit den Damen an. Wie so vieles standen auch die beiden WTA-Turniere der letzten Woche unter dem Eindruck des russischen Angriffskrieges in der Ukraine. Dayana Yastremska, die zu Beginn des Krieges noch aus ihrer Heimatstadt Odessa fliehen musste, konnte in Lyon nach Erhalt einer Wildcard das Finale erreichen. Zwar unterlag Yastremska dort der Chinesin Zhang Shuai. Doch am Ende stand zumindest sportlich eine erfolgreiche Woche. Für Zhang war es der dritte Titel ihrer Karriere. Svitolina verliert knapp In Monterrey schien die Topgesetzte Elina Svitolina zu einem ähnlichen Erfolgslauf anzusetzen wie ihre Landsfrau in Lyon. Doch am Ende scheiterte Svitolina in einem ganz engen Match an der Kolumbianerin Camila Osorio. Diese hielt sich auf dem Weg ins Finale ähnlich schadlos wie Leylah Fernandez. Der US Open Finalistin aus dem vergangenen Jahr war der Saisonstart zwar nicht so gelungen wie erhofft, doch hier konnte sie überzeugen. DTB qualifiziert sich nach viel Arbeit Bei den Herren stand in den letzten Tagen die Qualifikationsrunde für den Davis Cup auf dem Programm. Am Ende konnten sich die meisten Favoriten durchsetzen, so auch das deutsche Team. Gestärkt durch die Teilnahme von Alexander Zverev setzte sich die Auswahl des DTB mit 3:1 gegen Brasilien durch. Zverev hatte sich erst kurzfristig einsatzbereit gemeldet, wohl auch weil er in der Woche zuvor beim Turnier in Acapulco disqualifiziert worden war. Zverev hatte nach einer Doppelniederlage mit seinem Schläger vier Mal gegen den Stuhl des Schiedsrichters geschlagen und dabei nur knapp die Füße des Unparteiischen verpasst. In den News schauen Andreas und Philipp unter anderem auf Novak Djokovic. Der hat die Trennung von seinem Langzeitcoach Marian Vajda bekannt gegeben. Zeitgleich hat Andy Murray die Wiedervereinigung mit Ivan Lendl als Coach angekündigt. Zudem konnte die WTA einen neuen Titelsponsor verkünden.